biomodal and Element Biosciences Combine Duet Multiomic and High-Throughput Sequencing Capabilities to Advance Clinical Research
biomodal, an omics-based life sciences technology and analytics company, today announced at the AGBT 2026 General Meeting that biomodal’s duet multiomic solutions are compatible with Element Biosciences AVITI24™ 5D multiomics and AVITI™ sequencing instruments. Validated at the University of Minnesota (UMN) Genomics Center, this integration delivers enhanced sensitivity for applications including cancer, aging, and neurodegenerative disease with the aim of accelerating clinical research.
biomodal to Showcase Clinical Research for Earlier Detection of Colorectal Cancer at The Festival of Genomics and Biodata London 2026
biomodal, an omics-based life sciences technology and analytics company, today announced an upcoming presentation at the Festival of Genomics and Biodata London 2026 by Dr. Sophie Kirschner, Associate Director, Translational Medicine, Early Oncology at AstraZeneca. Dr. Kirschner will present data using biomodal’s 6-base multiomics sequencing solution, duet evoC, which simultaneously distinguishes between the canonical bases (A, C, G, T) and two functionally distinct epigenetic markers, 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), in cell-free DNA to provide a powerful advance over current methods used in liquid biopsy. Other methods either miss these critical epigenetic biomarkers or conflate them into a ‘modified cytosine’ readout.
